An interview with Alexander von Gabain, CSO of Intercell, one of the leading companies in the area of vaccine development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nbt.2009.01.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Joint Optimization of Bandwidth and Power Allocation in Uplink Systems with Deep Reinforcement Learning.
Sensors (Basel)
July 2023
Shaanxi Key Laboratory of Information Communication Network and Security, School of Communications and Information Engineering, Xi'an University of Posts and Telecommunications, Xi'an 710121, China.
Article Synopsis
- Future communication relies on optimizing wireless resource utilization to address issues like inter-cell interference in multi-user systems.
- The proposed joint-priority-based reinforcement learning (JPRL) approach aims to enhance both bandwidth and transmit power allocation to improve system throughput while ensuring quality of service (QoS).
- Results indicate that JPRL significantly outperforms other methods, achieving 10.4-15.5% higher average throughput than homogeneous-learning benchmarks and 17.3% better than the genetic algorithm.
Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules.
Sci Rep
June 2018
Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, 1090, Austria.
Immunosenescence is characterised by reduced B and T cell responses. Evidence shows that booster vaccinations are less effective in elderly people, but data on the efficacy of primary immunisation are sparse. We conducted a monocentric, open label, phase IV trial to compare immune responses to primary vaccinations using the inactivated, adjuvanted Japanese Encephalitis vaccine by 30 elderly people (mean 69, range 61-78 years) and 30 younger people (mean 24, range 18-30 years).
View Article and Find Full Text PDFIntercell - accelerating innovation.
N Biotechnol
April 2009
CeMM - Research Center for Molecular Medicine, Austrian Academy of Sciences, c/o Vienna Competence Center, Lazarettgasse 19, 3, 1090 Vienna, Austria.
An interview with Alexander von Gabain, CSO of Intercell, one of the leading companies in the area of vaccine development.
View Article and Find Full Text PDFProteomics approaches towards antigen discovery and vaccine development.
Curr Opin Mol Ther
June 2002
InterCell AG, Wien, Austria.
Vaccines have proved to be powerful medical interventions, and recent advances in immunology and in microbial pathogen genomics now allow the rational design of molecularly defined vaccines. Classical proteomics and immunoproteomics approaches such as serological proteome analysis (SERPA) have already provided first vaccine candidate antigens. The same is true for approaches based on recombinant DNA technology, and in the future protein arrays may further accelerate this kind of research.
View Article and Find Full Text PDFIdentification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.
Proc Natl Acad Sci U S A
May 2002
InterCell Biomedizinische Forschungs- und Entwicklungs-AG, Campus Vienna Biocenter 6, 1030 Vienna, Austria.
For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus, an important human pathogen. S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!